Benoit Destenaves

Title: Benoit Destenaves: Innovator in Genetic Markers for Growth Hormone Therapy

Introduction

Benoit Destenaves is a notable inventor based in Cambridge, GB. He has made significant contributions to the field of genetics, particularly in the context of growth hormone therapy. His work focuses on identifying genetic markers that can predict patient responses to treatment, which is crucial for effective medical interventions.

Latest Patents

Benoit Destenaves holds a patent titled "Genomic markers for prediction of long-term response to 2 years of growth hormone (GH) therapy." This invention relates to the use of genetic markers to identify the response to growth hormone treatment in patients with Growth Hormone Deficiency (GHD) or Turner Syndrome (TS). The patent also outlines a method for treating GHD or TS patients and includes kits for genotyping. He has 1 patent to his name.

Career Highlights

Benoit is associated with Ares Trading S.a., where he applies his expertise in genetics and biotechnology. His innovative approach has the potential to transform treatment protocols for patients suffering from hormonal deficiencies.

Collaborations

Benoit has collaborated with notable colleagues such as Pascal Croteau and Clement Olivier. Their combined efforts contribute to advancing research in genetic markers and their applications in medical treatments.

Conclusion

Benoit Destenaves is a pioneering inventor whose work in genetic markers for growth hormone therapy showcases the intersection of genetics and medicine. His contributions are vital for improving patient outcomes in hormonal treatments.